Reslizumab
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB06602 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 30 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | thrombocytopenia due to immune destruction | KG + DL |
| 2 | primary release disorder of platelets | KG + DL |
| 3 | pseudo-von Willebrand disease | KG + DL |
| 4 | autoimmune thrombocytopenic | KG + DL |
| 5 | Glanzmann thrombasthenia | KG + DL |
| 6 | neonatal thrombocytopenia | KG + DL |
| 7 | autosomal thrombocytopenia with normal platelets | KG + DL |
| 8 | Evans syndrome | KG + DL |
| 9 | filariasis | KG + DL |
| 10 | acne keloid | KG + DL |
| 11 | neonatal dermatomyositis | KG + DL |
| 12 | dermatitis | KG + DL |
| 13 | amyopathic dermatomyositis | KG + DL |
| 14 | acrodermatitis chronica atrophicans | KG + DL |
| 15 | mixed-type autoimmune hemolytic anemia | KG + DL |
| 16 | secondary interstitial lung disease specific to childhood associated with a connective tissue disease | KG + DL |
| 17 | hydroa vacciniforme, familial | KG + DL |
| 18 | drug-induced autoimmune hemolytic anemia | KG + DL |
| 19 | syndromic constitutional thrombocytopenia | KG + DL |
| 20 | neonatal autoimmune hemolytic anemia | KG + DL |
| 21 | proteinuria | KG + DL |
| 22 | fetal and neonatal alloimmune thrombocytopenia | KG + DL |
| 23 | hemorrhagic disorder due to a constitutional thrombocytopenia | KG + DL |
| 24 | bleeding diathesis due to a collagen receptor defect | KG + DL |
| 25 | Scott syndrome | KG + DL |
| 26 | severe nonproliferative diabetic retinopathy | KG + DL |
| 27 | paroxysmal nocturnal hemoglobinuria | KG + DL |
| 28 | infantile digital fibromatosis | KG + DL |
| 29 | Ledderhose disease | KG + DL |
| 30 | primary CD59 deficiency | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.